Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04363164 · ClinicalTrials.gov registry record · Phase 2
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
A Phase 2 study of Castration Resistant Metastatic Prostate Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 6
- Study locations
NCT04363164 is a Phase 2 study of Castration Resistant Metastatic Prostate Cancer that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 150 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT04363164, a Phase 2 study of Castration Resistant Metastatic Prostate Cancer, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 6
- Study locations
Study Summary
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.
Conditions Studied
Interventions
- DRUG Testosterone cypionate
- DRUG Enzalutamide
- DRUG Testosterone enanthate
Study Locations (6)
California
- University of California, San Diego (UCSD) - San Diego
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Massachusetts
- Dana-Faber Cancer Institute - Boston
Minnesota
- University of Minnesota - Minneapolis
Nebraska
- University of Nebraska Medical Center - Omaha
Washington
- University of Washington/Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04363164
The ClinicalTrials.gov registry entry for NCT04363164 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Castration Resistant Metastatic Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Testosterone cypionate is the first listed.
NCT04363164 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04363164 about?
NCT04363164 is a clinical study titled "Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression". Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objective...
What is the current status of trial NCT04363164?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2020-08-19. Estimated completion is 2027-07.
What conditions does trial NCT04363164 study?
This clinical trial studies the following conditions: Castration Resistant Metastatic Prostate Cancer.
What interventions are being tested in trial NCT04363164?
The interventions under investigation include: Testosterone cypionate (DRUG), Enzalutamide (DRUG), Testosterone enanthate (DRUG).
Who is sponsoring clinical trial NCT04363164?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04363164 being conducted?
This trial has 6 study locations across California, Maryland, Massachusetts, Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.